mProX™ Human IL3RA Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;HAECs

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Cancer Research

Related Diseases

Hairy Cell Leukemia; Diphtheria

Gene ID

Human:3563

UniProt ID

Human:P26951

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

IL3RA, also known as interleukin-3 receptor alpha, has been studied in various applications. In one study, IL3RA was identified as one of the immunological genes that are elevated in breast cancer patients with doxorubicin-induced cardiotoxicity. These immune-related genes were found to be associated with pathways involved in immune responses and cardiac function. Additionally, IL3RA and other immune-related genes were found to be significantly associated with poor survival prognosis in breast cancer patients and showed diagnostic efficacy in patients with breast cancer and heart failure. In another study, IL3RA was investigated in the context of acute myeloid leukemia (AML) immunotherapy. Epitope editing of donor hematopoietic stem/progenitor cells (HSPCs) using IL3RA and other genes enabled the targeting of essential genes for leukemia survival, reducing the risk of tumor immune escape. This approach showed resistance of epitope-edited hematopoiesis to chimeric antigen receptor (CAR) T cell treatment and eradication of AML xenografts. IL3RA was also found to be involved in the assembly of eukaryotic initiation factor 2 (eIF2), a key factor in protein synthesis and regulation. Mutations in IL3RA were associated with MEHMO syndrome, an X-linked intellectual disability. The structure of IL3RA bound to eIF2 was determined, providing insights into its mechanism of action. Finally, IL3RA was studied in the context of melanoma liver metastasis. Gene expression analysis revealed differential expression of IL3RA and other chemokine/cytokine receptors in invasive and non-invasive melanoma cell lines. Overexpression of IL3RA was also observed in primary melanoma tissues with liver metastasis. These findings suggest that IL3RA may play a role in organ-specific metastasis of melanoma cells to the liver. Overall, IL3RA has been implicated in various biological processes and may have potential applications in cancer research and immunotherapy.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human IL3RA Stable Cell Line (S01YF-1023-PY196). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Casey Williams (Verified Customer)

What is the significance of IL3RA in hematologic malignancies? May 25 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

IL3RA, also known as CD123, is a target for antibody-drug conjugates like BAY-943, showing efficacy in preclinical models of hematologic malignancies, indicating its potential as a therapeutic target. May 25 2023

chat Peyton Johnson (Verified Customer)

How does IL3RA expression influence the prognosis of acute myeloid leukemia? Mar 21 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Elevated expression of IL3RA in acute myeloid leukemia and infant ALL suggests its role as a potential target for biotherapy in these high-risk leukemias. Mar 21 2020

Published Data

Fig.1 The influence of HAECs is assessed by IL3RA suppression.

In the study, HAECs were subjected to incubation with medium containing IL3RA shRNA lentivirus or control shRNA lentivirus in 24-well plates for a duration of 48 hours. During this time frame, the observation of GFP expression in the cells infected with lentivirus was made using fluorescence microscopy. Furthermore, the analysis of IL3RA mRNA expression was carried out through RT-qPCR. The obtained values were compared with those of uninfected cells (referred to as Lenti (−)). The assessment of cell viability in IL3RA knockdown cells was performed using the trypan blue dye exclusion method. The resulting data, comprising the mean ± SEM (n = 8), were derived from two independent experiments, with statistical significance denoted by *** p < 0.001.

Ref: Saito-Takatsuji, Hidehito, et al. "Protective effects of collagen tripeptides in human aortic endothelial cells by restoring ROS-induced transcriptional repression." Nutrients 13.7 (2021): 2226.

Pubmed: 34209567

DOI: 10.3390/nu13072226

Research Highlights

Xiong, Daiqin. et al. "Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with Breast Cancer." Cardiovascular toxicology, 2023.
In a comprehensive analysis using bioinformatics and molecular docking studies, researchers identified key immune-related transcriptional markers linked to doxorubicin-induced cardiotoxicity in heart failure patients with breast cancer. They discovered 255 upregulated and 286 downregulated genes, including 58 elevated and 60 suppressed immunological genes, in patients with doxorubicin-induced heart failure. These genes are involved in pathways like B-cell receptor signaling and chemokine signaling. Some, such as IFIT5 and MS4A1, correlate with poor survival in breast cancer patients, indicating their potential as diagnostic markers for doxorubicin-induced cardiotoxicity. Validation in patient-derived cardiomyocytes confirmed the dysregulation of genes like RAD9A and GATA2, enhancing understanding of the disease's mechanism and pathogenesis.
Xiong, Daiqin. et al. "Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with Breast Cancer." Cardiovascular toxicology, 2023.
Pubmed: 37684436 DOI: 10.1007/s12012-023-09806-5

Casirati, Gabriele. et al. "Epitope editing enables targeted immunotherapy of acute myeloid leukaemia." Nature, 2023.
The efficacy of targeting dispensable lineage antigen, such as CD19, in the treatment of B cell acute lymphoblastic leukemia has been widely recognized. Despite the considerable success in this approach, more research is needed to fully understand and harness its potential. This abstract emphasizes the importance of utilizing lineage-specific antigens in cancer treatment, specifically in the context of B cell acute lymphoblastic leukemia. By targeting CD19, significant progress has been made, but further investigation and development is necessary to optimize this technique.
Casirati, Gabriele. et al. "Epitope editing enables targeted immunotherapy of acute myeloid leukaemia." Nature, 2023.
Pubmed: 37648862 DOI: 10.1038/s41586-023-06496-5